Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association

PB Duell, FK Welty, M Miller, A Chait… - … , and vascular biology, 2022‏ - ahajournals.org
Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is
believed to affect> 25% of adults worldwide. Unless specific testing is done to identify …

2019 Global NAFLD prevalence: a systematic review and meta-analysis

MH Le, YH Yeo, X Li, J Li, B Zou, Y Wu, Q Ye… - Clinical …, 2022‏ - Elsevier
Background & Aims The increasing rates of obesity and type 2 diabetes mellitus may lead to
increased prevalence of nonalcoholic fatty liver disease (NAFLD). We aimed to determine …

GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives

R Nevola, R Epifani, S Imbriani, G Tortorella… - International Journal of …, 2023‏ - mdpi.com
To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease,
affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available …

A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH

SM Francque, P Bedossa, V Ratziu… - … England Journal of …, 2021‏ - Mass Medical Soc
Background Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need.
Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that …

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020

K Tokushige, K Ikejima, M Ono, Y Eguchi… - Journal of …, 2021‏ - Springer
Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only
in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic …

Immunology of human fibrosis

M Bhattacharya, P Ramachandran - Nature Immunology, 2023‏ - nature.com
Fibrosis, defined by the excess deposition of structural and matricellular proteins in the
extracellular space, underlies tissue dysfunction in multiple chronic diseases. Approved …

Metabolic inflammation and insulin resistance in obesity

H Wu, CM Ballantyne - Circulation research, 2020‏ - ahajournals.org
Obesity is becoming an epidemic in the United States and worldwide and increases risk for
many diseases, particularly insulin resistance, type 2 diabetes mellitus, and cardiovascular …

[HTML][HTML] Liver fibrosis: mechanistic concepts and therapeutic perspectives

N Roehlen, E Crouchet, TF Baumert - Cells, 2020‏ - mdpi.com
Liver fibrosis due to viral or metabolic chronic liver diseases is a major challenge of global
health. Correlating with liver disease progression, fibrosis is a key factor for liver disease …

Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities

Y Wen, J Lambrecht, C Ju, F Tacke - Cellular & molecular immunology, 2021‏ - nature.com
Macrophages, which are key cellular components of the liver, have emerged as essential
players in the maintenance of hepatic homeostasis and in injury and repair processes in …

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

KC Lee, PS Wu, HC Lin - Clinical and molecular hepatology, 2022‏ - pmc.ncbi.nlm.nih.gov
The initial presentation of non-alcoholic steatohepatitis (NASH) is hepatic steatosis. The
dysfunction of lipid metabolism within hepatocytes caused by genetic factors, diet, and …